term trim pt
miss estim quarter deliv sale short
consensu forecast weak driven due
weak cath lab also seen peer result greater extent mix
disrupt lead mgmt disproportion focu away protect
pci/elect procedur reflect pressur mgmt initi
outlook call revenu growth management
wouldv consid like exactli exact magnitud
shortfal management outlin number initi address
issu note april reportedli promis fact management still
remain confid address market left room revis
guidanc next earn call suggest good chanc
upsid ou sale benefit broader
commerci japan boost recent cp reimburs
approv though feel good prospect beat prefer
wait quarter sign improv adjust
forecast accordingli also lower target multipl
reflect near-term risk subsequ pt move
stemi steam ahead posit management confirm fda approv
stemi trial pave way begin enrol
octob trial target time fairli consist
expect management indic trial cost run
miss fda commun earli februari
limit subset patient rp post-approv studi caus
outsiz reaction anticip physician thought
issu involv impella product believ abl
revers issu could take coupl quarter suspect
guidanc could revis upward sure like
occur like view
valuat maintain buy pt risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani report world-wide impella revenu
forecast impella revenu grow lighter
util growth mention previous product mix
neg impact februari dear letter issu fda
review higher mortal associ among sever patient implant
rp rectifi situat manag put substanti focu rp
shock patient expens protect pci procedur ou impella
revenu improv y/i revenu japan
sequenti flat contrast model pick-up japan thu result
fell short ou number manag anticip full year
japan contribut total march
receiv japanes reimburs approv impella cp
gross margin weaker forecast pressur
attribut manufactur invest direct labor cost sale
mix sg spend better model despit
expans commerci team invest toward japan launch
overal ebit margin lower model weaker
gross profit pull-through higher margin sum non-gaap ep
exclud one-tim invest gain excess tax benefit
miss forecast
actualsbtig estimate varianceu impella sale trial impella sale revenu growth net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani result includ excess tax benefit unreal gainon invest shockwav medic varianc
reflect shortfal view short-term pressur
high-risk pci busi first half trim revenu
go forward model revenu growth vs
previous addit commerci team on-going
invest tweak oper margin forecast
move adjust ep previous
forecast stabil market forecast revenu
growth also assum oper leverag improv translat
rate buy pt base month
revenu estim feel target multipl repres balanc view
compani above-averag revenu growth gross margin well
short-term disrupt caus rp issu importantli feel
multipl driver potenti upsid current estim includ label
expans stemi popul grow use among patient renal
failur acut kidney injuri geograph reach market risk
rate price target includ weak protect pci
reimburs cut slippag product timelin chang procedur
patent litig unsuccess data fda
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom ep btig estim compani filingsnewold changentm inc ingnnot technologiesirtcbuy factset data btig estimatespr ptpricemarket cap bp/e ex-amortev/salescagr
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
